FindTrial
Sign In

A new pharmaceutical care model construction and economic evaluation for anti-tuberculosis treatment drug monitoring

A new pharmaceutical care model construction and economic evaluation for anti-tuberculosis treatment drug monitoring

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074328
Enrollment
Unknown
Registered
2023-08-03
Start date
2023-08-15
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

TDM-Pharmaceutical Care Group:NA
TDM-Observation group:NA

Sponsors

Xi'an Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria (in accordance with the following three criteria) : TB infected or highly suspected TB infected patients admitted to our hospital since August 2028;Initial treatment with standardized first-line anti-tuberculosis therapy;Blood routine examination, liver and kidney function, sputum microscopic examination, sputum culture, etc.

Exclusion criteria

Exclusion criteria: Exclusion criteria (anyone) : age <18;Pregnant women;Severe liver injury;Severe kidney injury.

Design outcomes

Primary

MeasureTime frame
Time of sputum culture turn to negative;—

Secondary

MeasureTime frame
Serum concentration of isoniazid and rifampicin;Cost index;—

Countries

China

Contacts

Public ContactQian Lei

Xi'an Chest Hospital

362685867@qq.com+86 29 6250 0321

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026